CVS Health's poor 2024 performance could be turning around in 2025 with a new CEO and potential rebound, despite challenges.
Hosted on MSN8h
UnitedHealth's OptumRx Accused of Excessive Drug PricingThe Federal Trade Commission accused UnitedHealth's OptumRx, CVS Caremark, and Cigna's Express Scripts of pocketing over $7 ...
Hosted on MSN10h
Report Reveals Billions Made from Generic Drug Price HikesA recent Federal Trade Commission report highlights a concerning trend in the pharmaceutical industry, where pharmacy benefit ...
According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...
The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds or thousands ...
Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” fourth quarter ...
CVS Health shares are trading lower by 2.7% during Thursday's session. Shares of insurers and pharmacy benefit manager stocks ...
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback